{"id": "article-64046_0", "title": "Cannabidiol (CBD) -- Continuing Education Activity", "content": "This\u00a0activity focuses on cannabidiol's (CBD) role in\u00a0managing\u00a0refractory epilepsy.\u00a0Participants\u00a0will explore indications, actions, and contraindications pertinent to CBD's efficacy in managing Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This discussion also thoroughly reviews CBD's mechanism of action, adverse event profile, and ongoing research trials involving this drug. Additionally, understanding CBD's pharmacology\u00a0helps healthcare professionals\u00a0to tailor treatment plans to individual patient needs. Enhancing patient care and optimizing outcomes in epilepsy, neuropathic pain, and anxiety disorders\u00a0requires\u00a0emphasis on the critical role of the interprofessional healthcare team in overseeing CBD therapy.", "contents": "Cannabidiol (CBD) -- Continuing Education Activity. This\u00a0activity focuses on cannabidiol's (CBD) role in\u00a0managing\u00a0refractory epilepsy.\u00a0Participants\u00a0will explore indications, actions, and contraindications pertinent to CBD's efficacy in managing Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This discussion also thoroughly reviews CBD's mechanism of action, adverse event profile, and ongoing research trials involving this drug. Additionally, understanding CBD's pharmacology\u00a0helps healthcare professionals\u00a0to tailor treatment plans to individual patient needs. Enhancing patient care and optimizing outcomes in epilepsy, neuropathic pain, and anxiety disorders\u00a0requires\u00a0emphasis on the critical role of the interprofessional healthcare team in overseeing CBD therapy."}
{"id": "article-64046_1", "title": "Cannabidiol (CBD) -- Continuing Education Activity", "content": "Objectives: Identify\u00a0the indications for cannabidiol. Determine\u00a0the importance of monitoring patients receiving cannabidiol therapy. Assess contraindications and other relevant factors before prescribing cannabidiol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from cannabidiol therapy. Access free multiple choice questions on this topic.", "contents": "Cannabidiol (CBD) -- Continuing Education Activity. Objectives: Identify\u00a0the indications for cannabidiol. Determine\u00a0the importance of monitoring patients receiving cannabidiol therapy. Assess contraindications and other relevant factors before prescribing cannabidiol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from cannabidiol therapy. Access free multiple choice questions on this topic."}
{"id": "article-64046_2", "title": "Cannabidiol (CBD) -- Indications", "content": "Cannabis sativa , or Indian hemp (subfamily Cannaboideae of family Moraceae ), is an annual herbaceous plant native to central and western Asia. The plant is cultivated for its medicinal properties and\u00a0as a natural textile fiber. Cannabis sativa contains over 400 chemical compounds; approximately 80 are biologically active. The most\u00a0relevant cannabis compounds are cannabinoids, which are formed by a terpene combined with resorcinol (or\u00a0a benzopyranic ring system, according to a different nomenclature). There are about\u00a060 cannabinoids. The most important psychoactive compound is tetrahydrocannabinol (THC), particularly the isomer delta (\u03949-THC). Other\u00a0relevant compounds\u00a0include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and olivetol. In addition to cannabinoids, the plant contains terpenoids such as \u03b2-myrcene, \u03b2-caryophyllene, D-limonene, linalool, piperidine, and P-cymene, as well as flavonoids such as quercetin.", "contents": "Cannabidiol (CBD) -- Indications. Cannabis sativa , or Indian hemp (subfamily Cannaboideae of family Moraceae ), is an annual herbaceous plant native to central and western Asia. The plant is cultivated for its medicinal properties and\u00a0as a natural textile fiber. Cannabis sativa contains over 400 chemical compounds; approximately 80 are biologically active. The most\u00a0relevant cannabis compounds are cannabinoids, which are formed by a terpene combined with resorcinol (or\u00a0a benzopyranic ring system, according to a different nomenclature). There are about\u00a060 cannabinoids. The most important psychoactive compound is tetrahydrocannabinol (THC), particularly the isomer delta (\u03949-THC). Other\u00a0relevant compounds\u00a0include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and olivetol. In addition to cannabinoids, the plant contains terpenoids such as \u03b2-myrcene, \u03b2-caryophyllene, D-limonene, linalool, piperidine, and P-cymene, as well as flavonoids such as quercetin."}
{"id": "article-64046_3", "title": "Cannabidiol (CBD) -- Indications", "content": "CBD is nonintoxicating as it does not\u00a0demonstrate psychoactive activity. However, it exerts several beneficial pharmacological effects. The compound has analgesic and anti-inflammatory activities mediated by inhibiting cyclooxygenase and lipoxygenase. This anti-inflammatory action is several hundred times\u00a0more potent than acetylsalicylic acid. Furthermore, cannabidiol inhibits the synthesis of leukotriene TXB4 in polymorphonuclear cells. [1] Several investigations have\u00a0confirmed\u00a0CBD's anxiolytic, antiemetic, antipsychotic, and neuroprotective antioxidant properties. [2] [3]", "contents": "Cannabidiol (CBD) -- Indications. CBD is nonintoxicating as it does not\u00a0demonstrate psychoactive activity. However, it exerts several beneficial pharmacological effects. The compound has analgesic and anti-inflammatory activities mediated by inhibiting cyclooxygenase and lipoxygenase. This anti-inflammatory action is several hundred times\u00a0more potent than acetylsalicylic acid. Furthermore, cannabidiol inhibits the synthesis of leukotriene TXB4 in polymorphonuclear cells. [1] Several investigations have\u00a0confirmed\u00a0CBD's anxiolytic, antiemetic, antipsychotic, and neuroprotective antioxidant properties. [2] [3]"}
{"id": "article-64046_4", "title": "Cannabidiol (CBD) -- Indications", "content": "In a recent document, the FDA highlighted the potential beneficial effects of cannabis derivatives. To date, the agency has not approved a marketing application for cannabis,\u00a0but it has approved\u00a04 synthetic cannabis-related drug products. A licensed healthcare provider must prescribe these approved drugs. In brief, the FDA-approved products are as follows: Synthetic cannabis-related drug products Two products containing the active ingredient dronabinol (a synthetic \u03949-THC) for the treatment of anorexia associated with weight loss in patients with AIDS. [4] A product containing nabilone\u00a0that is prescribed\u00a0for the treatment of nausea and vomiting associated with anticancer\u00a0chemotherapy. [5] The cannabis-derived compound\u00a0cannabidiol", "contents": "Cannabidiol (CBD) -- Indications. In a recent document, the FDA highlighted the potential beneficial effects of cannabis derivatives. To date, the agency has not approved a marketing application for cannabis,\u00a0but it has approved\u00a04 synthetic cannabis-related drug products. A licensed healthcare provider must prescribe these approved drugs. In brief, the FDA-approved products are as follows: Synthetic cannabis-related drug products Two products containing the active ingredient dronabinol (a synthetic \u03949-THC) for the treatment of anorexia associated with weight loss in patients with AIDS. [4] A product containing nabilone\u00a0that is prescribed\u00a0for the treatment of nausea and vomiting associated with anticancer\u00a0chemotherapy. [5] The cannabis-derived compound\u00a0cannabidiol"}
{"id": "article-64046_5", "title": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications", "content": "The FDA-approved pharmaceutical-grade cannabidiol for\u00a0patients 1 year or older\u00a0with refractory seizures as a result of the following conditions: Lennox-Gastaut syndrome Dravet syndrome Tuberous sclerosis complex [6] [7]", "contents": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications. The FDA-approved pharmaceutical-grade cannabidiol for\u00a0patients 1 year or older\u00a0with refractory seizures as a result of the following conditions: Lennox-Gastaut syndrome Dravet syndrome Tuberous sclerosis complex [6] [7]"}
{"id": "article-64046_6", "title": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications", "content": "Lennox-Gastaut syndrome is characterized by multiple types of seizures, with the most common being tonic seizures. On EEG, it has a characteristic slow wave (<3 Hz) with a spike or sharp wave. The exact pathophysiology is unknown. First-line treatment consists of various antiepileptic drugs, with CBD\u00a0as adjuvant therapy. Children with Lennox-Gastaut syndrome usually have learning and intellectual disabilities. [8]", "contents": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications. Lennox-Gastaut syndrome is characterized by multiple types of seizures, with the most common being tonic seizures. On EEG, it has a characteristic slow wave (<3 Hz) with a spike or sharp wave. The exact pathophysiology is unknown. First-line treatment consists of various antiepileptic drugs, with CBD\u00a0as adjuvant therapy. Children with Lennox-Gastaut syndrome usually have learning and intellectual disabilities. [8]"}
{"id": "article-64046_7", "title": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications", "content": "Dravet syndrome\u00a0is typically diagnosed in\u00a01-year-old children with frequent febrile seizures.\u00a0As the disease progresses, other seizures may develop, including status epilepticus. An EEG will initially be normal before progressing to slowing and severe generalized polyspikes. Dravet syndrome appears to be caused by a nonsense mutation in the SCN1A gene, though there are cases without this mutation. Treatment was purely symptomatic, with benzodiazepines and antiepileptics prescribed to prevent the development of status epilepticus. Children with Dravet syndrome often have motor, intellectual, and psychological disabilities. [9]", "contents": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications. Dravet syndrome\u00a0is typically diagnosed in\u00a01-year-old children with frequent febrile seizures.\u00a0As the disease progresses, other seizures may develop, including status epilepticus. An EEG will initially be normal before progressing to slowing and severe generalized polyspikes. Dravet syndrome appears to be caused by a nonsense mutation in the SCN1A gene, though there are cases without this mutation. Treatment was purely symptomatic, with benzodiazepines and antiepileptics prescribed to prevent the development of status epilepticus. Children with Dravet syndrome often have motor, intellectual, and psychological disabilities. [9]"}
{"id": "article-64046_8", "title": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications", "content": "After conducting an\u00a0assessment\u00a0of\u00a0randomized controlled trials evaluating the efficacy of CBD\u00a0for managing Lennox\u2013Gastaut (LGS) and Dravet syndromes (DS), a pharmaceutical-grade CBD formulation\u00a0received\u00a0approval from the U.S. Food and Drug Administration (FDA) in 2018. [7] [10] [11]", "contents": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications. After conducting an\u00a0assessment\u00a0of\u00a0randomized controlled trials evaluating the efficacy of CBD\u00a0for managing Lennox\u2013Gastaut (LGS) and Dravet syndromes (DS), a pharmaceutical-grade CBD formulation\u00a0received\u00a0approval from the U.S. Food and Drug Administration (FDA) in 2018. [7] [10] [11]"}
{"id": "article-64046_9", "title": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications", "content": "Management of\u00a0seizures in patients with tuberous sclerosis complex (TSC) is generally\u00a0similar\u00a0to the approach for other epileptic conditions. Regulatory agencies have approved a specific formulation of pharmaceutical-grade CBD to treat seizures associated with TSC. [12]", "contents": "Cannabidiol (CBD) -- Indications -- FDA-Approved Indications. Management of\u00a0seizures in patients with tuberous sclerosis complex (TSC) is generally\u00a0similar\u00a0to the approach for other epileptic conditions. Regulatory agencies have approved a specific formulation of pharmaceutical-grade CBD to treat seizures associated with TSC. [12]"}
{"id": "article-64046_10", "title": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses", "content": "According to the guidelines established by the American Society of Clinical Oncology (ASCO), for patients undergoing cancer treatment with refractory nausea or vomiting despite adhering to antiemetic prophylaxis protocols, clinicians may consider adding dronabinol, nabilone, or a quality-controlled oral 1:1 tetrahydrocannabinol/cannabidiol extract. Cannabis or cannabinoids\u00a0are just one alternative for refractory nausea and vomiting in adult\u00a0patients with cancer despite optimal prophylaxis. In\u00a0these cases, the ASCO guidelines suggest considering the addition of olanzapine or introducing a different antiemetic, such as a neurokinin-1 (NK-1) receptor antagonist, benzodiazepine, or dopamine antagonist. [13]", "contents": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses. According to the guidelines established by the American Society of Clinical Oncology (ASCO), for patients undergoing cancer treatment with refractory nausea or vomiting despite adhering to antiemetic prophylaxis protocols, clinicians may consider adding dronabinol, nabilone, or a quality-controlled oral 1:1 tetrahydrocannabinol/cannabidiol extract. Cannabis or cannabinoids\u00a0are just one alternative for refractory nausea and vomiting in adult\u00a0patients with cancer despite optimal prophylaxis. In\u00a0these cases, the ASCO guidelines suggest considering the addition of olanzapine or introducing a different antiemetic, such as a neurokinin-1 (NK-1) receptor antagonist, benzodiazepine, or dopamine antagonist. [13]"}
{"id": "article-64046_11", "title": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses", "content": "CBD is currently under investigation as a potential therapy for various psychiatric, neurodegenerative, and inflammatory diseases. [14] [15] Current clinical studies are investigating the use of CBD\u00a0for mood disorders such as anxiety, chronic pain control, anti-inflammatory diseases, and neurodegenerative diseases such as Alzheimer and Parkinson disease. However, none of these trials have resulted in FDA approval of CBD oil for the management of these conditions. [16] [17]", "contents": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses. CBD is currently under investigation as a potential therapy for various psychiatric, neurodegenerative, and inflammatory diseases. [14] [15] Current clinical studies are investigating the use of CBD\u00a0for mood disorders such as anxiety, chronic pain control, anti-inflammatory diseases, and neurodegenerative diseases such as Alzheimer and Parkinson disease. However, none of these trials have resulted in FDA approval of CBD oil for the management of these conditions. [16] [17]"}
{"id": "article-64046_12", "title": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses", "content": "One study was conducted to investigate the effectiveness of acute migraine treatments using a combination of 6% tetrahydrocannabinol (THC) and 11% cannabidiol (CBD) compared to placebo. The results revealed that the combination treatment was notably more effective than placebo at the 2-hour mark post-treatment. Furthermore, the benefits of this treatment were sustained, with continued efficacy\u00a0noted at the 24-hour and 48-hour intervals. [18]", "contents": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses. One study was conducted to investigate the effectiveness of acute migraine treatments using a combination of 6% tetrahydrocannabinol (THC) and 11% cannabidiol (CBD) compared to placebo. The results revealed that the combination treatment was notably more effective than placebo at the 2-hour mark post-treatment. Furthermore, the benefits of this treatment were sustained, with continued efficacy\u00a0noted at the 24-hour and 48-hour intervals. [18]"}
{"id": "article-64046_13", "title": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses", "content": "An open-label, single-center, phase I trial evaluated CBD for patients with biochemically recurrent prostate cancer after primary definitive local therapy. CBD was initiated at 600 mg orally once daily, with escalation to 800 mg daily. At 12 weeks, 16 out of 18 patients (88%) were found to have\u00a0stable biochemical disease, with\u00a01 patient demonstrating partial biochemical response and another experiencing elevated PSA levels. Patient-reported outcomes did not significantly change, but trends indicated improved tolerability of CBD, particularly in emotional functioning. Daily CBD dosage of 800 mg appeared safe and well-tolerated, warranting further investigation. [19] One recent cohort study has indicated that CBD demonstrates an antiseizure effect similar to that of conventional antiseizure medications, showing a favorable safety profile across different epilepsy subtypes. [20] THC/CBD formulations are used at higher dosages to treat spasticity in amyotrophic lateral sclerosis (ALS). However, further prospective studies and direct comparisons with other anti-spasticity medications are required to understand the efficacy and safety profile more clearly. [21]", "contents": "Cannabidiol (CBD) -- Indications -- Off-Label and Investigational Uses. An open-label, single-center, phase I trial evaluated CBD for patients with biochemically recurrent prostate cancer after primary definitive local therapy. CBD was initiated at 600 mg orally once daily, with escalation to 800 mg daily. At 12 weeks, 16 out of 18 patients (88%) were found to have\u00a0stable biochemical disease, with\u00a01 patient demonstrating partial biochemical response and another experiencing elevated PSA levels. Patient-reported outcomes did not significantly change, but trends indicated improved tolerability of CBD, particularly in emotional functioning. Daily CBD dosage of 800 mg appeared safe and well-tolerated, warranting further investigation. [19] One recent cohort study has indicated that CBD demonstrates an antiseizure effect similar to that of conventional antiseizure medications, showing a favorable safety profile across different epilepsy subtypes. [20] THC/CBD formulations are used at higher dosages to treat spasticity in amyotrophic lateral sclerosis (ALS). However, further prospective studies and direct comparisons with other anti-spasticity medications are required to understand the efficacy and safety profile more clearly. [21]"}
{"id": "article-64046_14", "title": "Cannabidiol (CBD) -- Mechanism of Action", "content": "The mechanism of action for cannabidiol, especially concerning its anticonvulsant effect, has not been fully elucidated. CBD is known to have a low affinity for cannabinoid receptors CB1 and CB2, where it can\u00a0act as\u00a0an\u00a0agonist or antagonist.\u00a0The anti-inflammatory effects of CBD may be explained by its inverse agonist activity at the CB2 receptor. [22] Cannabidiol is a partial agonist of the serotonin 5-HT1A receptor and an allosteric modulator of opioid receptors, specifically\u00a0\u03bc and \u03b4. Researchers postulate that CBD could agonize PPAR-\u03b3 and affect intracellular calcium release. [16] [23]", "contents": "Cannabidiol (CBD) -- Mechanism of Action. The mechanism of action for cannabidiol, especially concerning its anticonvulsant effect, has not been fully elucidated. CBD is known to have a low affinity for cannabinoid receptors CB1 and CB2, where it can\u00a0act as\u00a0an\u00a0agonist or antagonist.\u00a0The anti-inflammatory effects of CBD may be explained by its inverse agonist activity at the CB2 receptor. [22] Cannabidiol is a partial agonist of the serotonin 5-HT1A receptor and an allosteric modulator of opioid receptors, specifically\u00a0\u03bc and \u03b4. Researchers postulate that CBD could agonize PPAR-\u03b3 and affect intracellular calcium release. [16] [23]"}
{"id": "article-64046_15", "title": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Cannabidiol typically reaches peak plasma concentration (Tmax)\u00a0between 2.5 and 5 hours. Coadministration with a high-fat, high-calorie meal significantly increases maximum plasma concentration (Cmax) and area under the curve (AUC) compared to fasting. A low-fat, low-calorie meal also\u00a0increases\u00a0Cmax and AUC, though to a lesser extent.\u00a0Administration of\u00a0CBD with bovine milk or alcohol results in higher Cmax and AUC. Bioavailability through inhalation (smoking) is approximately 31%. Distribution: Cannabidiol's volume of distribution (Vd) ranges from 20,963 L to 42,849 L in healthy volunteers. CBD and its metabolites\u00a0are more than 94% protein-bound.", "contents": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics. Absorption: Cannabidiol typically reaches peak plasma concentration (Tmax)\u00a0between 2.5 and 5 hours. Coadministration with a high-fat, high-calorie meal significantly increases maximum plasma concentration (Cmax) and area under the curve (AUC) compared to fasting. A low-fat, low-calorie meal also\u00a0increases\u00a0Cmax and AUC, though to a lesser extent.\u00a0Administration of\u00a0CBD with bovine milk or alcohol results in higher Cmax and AUC. Bioavailability through inhalation (smoking) is approximately 31%. Distribution: Cannabidiol's volume of distribution (Vd) ranges from 20,963 L to 42,849 L in healthy volunteers. CBD and its metabolites\u00a0are more than 94% protein-bound."}
{"id": "article-64046_16", "title": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Cannabidiol\u00a0is metabolized primarily in the liver and intestines by CYP3A4 and CYP2C19 enzymes. CBD inhibits\u00a0UDP-glucuronosyltransferase (UGT) enzymes, including UGT1A9, UGT1A6, UGT2B7 and UGT2B4. [24]", "contents": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics. Metabolism: Cannabidiol\u00a0is metabolized primarily in the liver and intestines by CYP3A4 and CYP2C19 enzymes. CBD inhibits\u00a0UDP-glucuronosyltransferase (UGT) enzymes, including UGT1A9, UGT1A6, UGT2B7 and UGT2B4. [24]"}
{"id": "article-64046_17", "title": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: Cannabidiol is primarily excreted in feces and minimally in urine. CBD's half-life after oromucosal administration (spray) is between\u00a01.4 and 10.9\u00a0hours, 2 and 5 days after chronic oral consumption, and 31 hours after smoking. [25]", "contents": "Cannabidiol (CBD) -- Mechanism of Action -- Pharmacokinetics. Excretion: Cannabidiol is primarily excreted in feces and minimally in urine. CBD's half-life after oromucosal administration (spray) is between\u00a01.4 and 10.9\u00a0hours, 2 and 5 days after chronic oral consumption, and 31 hours after smoking. [25]"}
{"id": "article-64046_18", "title": "Cannabidiol (CBD) -- Administration -- Available Dosage Forms and Strength", "content": "Cannabidiol is typically administered orally. [26] When needed, cannabidiol\u00a0may be administered through nasogastric or gastrostomy tubes.\u00a0Pharmaceutical CBD oil is available as an\u00a0oral solution\u00a0with a 100\u00a0mg/mL dosage.", "contents": "Cannabidiol (CBD) -- Administration -- Available Dosage Forms and Strength. Cannabidiol is typically administered orally. [26] When needed, cannabidiol\u00a0may be administered through nasogastric or gastrostomy tubes.\u00a0Pharmaceutical CBD oil is available as an\u00a0oral solution\u00a0with a 100\u00a0mg/mL dosage."}
{"id": "article-64046_19", "title": "Cannabidiol (CBD) -- Administration -- Adult Dosage", "content": "Lennox-Gastaut Syndrome or Dravet Syndrome: Dosing with CBD should begin at lower\u00a0concentrations and titrate up to clinical levels.\u00a0In patients 12 months and older, the initial dose should be 2.5 mg/kg orally twice daily. The maintenance dose is 10 to 20 mg/kg/d. If the patient has tolerated CBD therapy for\u00a0a week, the dose may be increased to 5 mg/kg twice daily. The dose can be increased by 2.5 mg/kg twice daily, every other day, as tolerated.\u00a0For patients with Lennox-Gastaut Syndrome, the maximum dose is 20 mg/kg/d. For patients with Dravet syndrome, the maximum dose is 20 mg/kg/d. Patients who need a more rapid titration may gradually increase the dose daily. [27] [28]", "contents": "Cannabidiol (CBD) -- Administration -- Adult Dosage. Lennox-Gastaut Syndrome or Dravet Syndrome: Dosing with CBD should begin at lower\u00a0concentrations and titrate up to clinical levels.\u00a0In patients 12 months and older, the initial dose should be 2.5 mg/kg orally twice daily. The maintenance dose is 10 to 20 mg/kg/d. If the patient has tolerated CBD therapy for\u00a0a week, the dose may be increased to 5 mg/kg twice daily. The dose can be increased by 2.5 mg/kg twice daily, every other day, as tolerated.\u00a0For patients with Lennox-Gastaut Syndrome, the maximum dose is 20 mg/kg/d. For patients with Dravet syndrome, the maximum dose is 20 mg/kg/d. Patients who need a more rapid titration may gradually increase the dose daily. [27] [28]"}
{"id": "article-64046_20", "title": "Cannabidiol (CBD) -- Administration -- Tuberous Sclerosis Complex", "content": "The initial suggested dose is 2.5 mg/kg orally twice daily (equivalent to 5 mg/kg/d). This dosage may be increased weekly by 2.5 mg/kg (equivalent to 5 mg/kg/d) as tolerated, up to a maintenance dose of 12.5 mg/kg orally twice daily (equivalent to 25 mg/kg/d). [29]", "contents": "Cannabidiol (CBD) -- Administration -- Tuberous Sclerosis Complex. The initial suggested dose is 2.5 mg/kg orally twice daily (equivalent to 5 mg/kg/d). This dosage may be increased weekly by 2.5 mg/kg (equivalent to 5 mg/kg/d) as tolerated, up to a maintenance dose of 12.5 mg/kg orally twice daily (equivalent to 25 mg/kg/d). [29]"}
{"id": "article-64046_21", "title": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: Dosages must be\u00a0titrated slowly\u00a0for patients with hepatic impairment, as\u00a0cannabidiol can cause liver damage.\u00a0CBD dosing remains unchanged in individuals with mild (Child-Pugh A) hepatic impairment. [27] According to FDA-approved product labeling, the recommended dosage for hepatic impairment is as follows: Renal impairment: The product labeling does not provide dosage adjustments for cannabidiol\u00a0due to impaired kidney function.", "contents": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations. Hepatic impairment: Dosages must be\u00a0titrated slowly\u00a0for patients with hepatic impairment, as\u00a0cannabidiol can cause liver damage.\u00a0CBD dosing remains unchanged in individuals with mild (Child-Pugh A) hepatic impairment. [27] According to FDA-approved product labeling, the recommended dosage for hepatic impairment is as follows: Renal impairment: The product labeling does not provide dosage adjustments for cannabidiol\u00a0due to impaired kidney function."}
{"id": "article-64046_22", "title": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: The American College of Obstetricians and Gynecologists (ACOG) advises healthcare providers to inquire about substance use, including marijuana, before and during pregnancy. Pregnant women should be counseled on the potential risks associated with marijuana use and encouraged to stop using it. [30] Pregnant women using cannabidiol should be encouraged to participate in pregnancy registries. There is insufficient data\u00a0concerning the effect of\u00a0cannabidiol on fetal development during pregnancy. Preclinical investigations have demonstrated that high doses of fetal CBD exposure may\u00a0alter\u00a0thermal pain sensitivity, problem-solving behaviors, and the excitability of pyramidal neurons in the prefrontal cortex. CBD intake during pregnancy may\u00a0have detrimental long-term neurodevelopmental consequences. [31]", "contents": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations. Pregnancy considerations: The American College of Obstetricians and Gynecologists (ACOG) advises healthcare providers to inquire about substance use, including marijuana, before and during pregnancy. Pregnant women should be counseled on the potential risks associated with marijuana use and encouraged to stop using it. [30] Pregnant women using cannabidiol should be encouraged to participate in pregnancy registries. There is insufficient data\u00a0concerning the effect of\u00a0cannabidiol on fetal development during pregnancy. Preclinical investigations have demonstrated that high doses of fetal CBD exposure may\u00a0alter\u00a0thermal pain sensitivity, problem-solving behaviors, and the excitability of pyramidal neurons in the prefrontal cortex. CBD intake during pregnancy may\u00a0have detrimental long-term neurodevelopmental consequences. [31]"}
{"id": "article-64046_23", "title": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Cannabidiol has not been\u00a0investigated in women who are breastfeeding. Due to the lack of published data on cannabidiol as an antiepileptic during breastfeeding, an alternative medication is advised, particularly when preterm infants are being nursed. [32] Pediatric patients: The FDA has approved cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in all age groups. Older patients: Clinicians should initiate CBD\u00a0therapy\u00a0at lower\u00a0doses\u00a0for older\u00a0adults due to potential reductions in renal and hepatic function and concurrent drug therapy.", "contents": "Cannabidiol (CBD) -- Administration -- Specific Patient Populations. Breastfeeding considerations: Cannabidiol has not been\u00a0investigated in women who are breastfeeding. Due to the lack of published data on cannabidiol as an antiepileptic during breastfeeding, an alternative medication is advised, particularly when preterm infants are being nursed. [32] Pediatric patients: The FDA has approved cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in all age groups. Older patients: Clinicians should initiate CBD\u00a0therapy\u00a0at lower\u00a0doses\u00a0for older\u00a0adults due to potential reductions in renal and hepatic function and concurrent drug therapy."}
{"id": "article-64046_24", "title": "Cannabidiol (CBD) -- Adverse Effects -- Liver Damage", "content": "CBD can cause dose-dependent\u00a0hepatotoxicity. Concomitant use of CBD and other medications, including leflunomide, lomitapide, mipomersen, pexidartinib, teriflunomide, and valproate, is known to cause liver damage. Clinicians should warn patients with elevated baseline transaminase levels about the risk of exacerbating liver function\u00a0while taking CBD. Providers should monitor bilirubin and transaminase levels before and during treatment.\u00a0According to ASCO guidelines, hepatotoxicity is\u00a0primarily observed\u00a0when\u00a0CBD is administered orally at daily doses of 300 mg or greater. [13] Discontinuation of CBD or discontinuing concomitant use reduces these elevations. In patients with moderate or severe liver damage, slow titration and dosage adjustment\u00a0are\u00a0recommended. [33] [34]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Liver Damage. CBD can cause dose-dependent\u00a0hepatotoxicity. Concomitant use of CBD and other medications, including leflunomide, lomitapide, mipomersen, pexidartinib, teriflunomide, and valproate, is known to cause liver damage. Clinicians should warn patients with elevated baseline transaminase levels about the risk of exacerbating liver function\u00a0while taking CBD. Providers should monitor bilirubin and transaminase levels before and during treatment.\u00a0According to ASCO guidelines, hepatotoxicity is\u00a0primarily observed\u00a0when\u00a0CBD is administered orally at daily doses of 300 mg or greater. [13] Discontinuation of CBD or discontinuing concomitant use reduces these elevations. In patients with moderate or severe liver damage, slow titration and dosage adjustment\u00a0are\u00a0recommended. [33] [34]"}
{"id": "article-64046_25", "title": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects", "content": "Reports of malaise, asthenia, and sedation associated with CBD use have been documented. These\u00a0adverse\u00a0effects may diminish over time and are more likely to be reported earlier in treatment. A meta-analysis demonstrated that CBD treatment is linked to somnolence, diarrhea, and transaminitis. [35]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects. Reports of malaise, asthenia, and sedation associated with CBD use have been documented. These\u00a0adverse\u00a0effects may diminish over time and are more likely to be reported earlier in treatment. A meta-analysis demonstrated that CBD treatment is linked to somnolence, diarrhea, and transaminitis. [35]"}
{"id": "article-64046_26", "title": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects", "content": "Cannabidiol\u00a0may\u00a0be associated with\u00a0increased suicidal thoughts and behaviors. [36] When prescribing CBD, the physician should warn patients and caregivers to watch for any unusual changes in mood or behaviors. Any changes require evaluating whether they result from\u00a0CBD, other medications, or underlying illnesses.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects. Cannabidiol\u00a0may\u00a0be associated with\u00a0increased suicidal thoughts and behaviors. [36] When prescribing CBD, the physician should warn patients and caregivers to watch for any unusual changes in mood or behaviors. Any changes require evaluating whether they result from\u00a0CBD, other medications, or underlying illnesses."}
{"id": "article-64046_27", "title": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects", "content": "CBD is only recently available and is usually used as an adjunct therapy; further\u00a0investigations\u00a0are necessary to better\u00a0comprehend potential\u00a0adverse\u00a0effects and effects on liver enzymes and drug interactions. [37] [1] Post-marketing surveillance has revealed cortical visual impairment and a hyperactive pharyngeal reflex as potential adverse effects of CBD. [38]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Other Adverse Effects. CBD is only recently available and is usually used as an adjunct therapy; further\u00a0investigations\u00a0are necessary to better\u00a0comprehend potential\u00a0adverse\u00a0effects and effects on liver enzymes and drug interactions. [37] [1] Post-marketing surveillance has revealed cortical visual impairment and a hyperactive pharyngeal reflex as potential adverse effects of CBD. [38]"}
{"id": "article-64046_28", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "The coadministration of rifampin, a strong CYP3A4 inducer, decreases plasma concentrations of cannabidiol. [39]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. The coadministration of rifampin, a strong CYP3A4 inducer, decreases plasma concentrations of cannabidiol. [39]"}
{"id": "article-64046_29", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Cannabidiol weakly inhibits CYP1A2, potentially increasing exposure to caffeine, theophylline, or tizanidine.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Cannabidiol weakly inhibits CYP1A2, potentially increasing exposure to caffeine, theophylline, or tizanidine."}
{"id": "article-64046_30", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "In vitro data suggest potential drug-drug interactions with CYP2B6 substrates, including bupropion and efavirenz, UGT1A9 substrates (eg, propofol and fenofibrate), and UGT2B7 substrates (eg, gemfibrozil, lamotrigine, morphine, and lorazepam) when coadministered with cannabidiol. Cannabidiol may also interact with CYP2C8 and CYP2C9 substrates such as phenytoin. Dosage adjustments of these substrates may be necessary if adverse reactions occur\u00a0during coadministration.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. In vitro data suggest potential drug-drug interactions with CYP2B6 substrates, including bupropion and efavirenz, UGT1A9 substrates (eg, propofol and fenofibrate), and UGT2B7 substrates (eg, gemfibrozil, lamotrigine, morphine, and lorazepam) when coadministered with cannabidiol. Cannabidiol may also interact with CYP2C8 and CYP2C9 substrates such as phenytoin. Dosage adjustments of these substrates may be necessary if adverse reactions occur\u00a0during coadministration."}
{"id": "article-64046_31", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of cannabidiol may increase plasma concentrations of drugs metabolized by CYP2C19 (eg, diazepam), potentially raising the risk of adverse reactions. Reducing the dosage of sensitive CYP2C19 substrates may be\u00a0necessary when coadministered with cannabidiol.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Coadministration of cannabidiol may increase plasma concentrations of drugs metabolized by CYP2C19 (eg, diazepam), potentially raising the risk of adverse reactions. Reducing the dosage of sensitive CYP2C19 substrates may be\u00a0necessary when coadministered with cannabidiol."}
{"id": "article-64046_32", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Cannabidiol coadministration increases plasma concentrations of N-desmethyl clobazam, the active metabolite of clobazam. If adverse reactions occur with cannabidiol coadministration, clobazam dose reduction should be considered.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Cannabidiol coadministration increases plasma concentrations of N-desmethyl clobazam, the active metabolite of clobazam. If adverse reactions occur with cannabidiol coadministration, clobazam dose reduction should be considered."}
{"id": "article-64046_33", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Concomitant use of cannabidiol and stiripentol may\u00a0increase exposure to stiripentol, though the mechanism of this interaction is unclear. Patients should be monitored for stiripentol-related adverse drug reactions. [40]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Concomitant use of cannabidiol and stiripentol may\u00a0increase exposure to stiripentol, though the mechanism of this interaction is unclear. Patients should be monitored for stiripentol-related adverse drug reactions. [40]"}
{"id": "article-64046_34", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of cannabidiol with everolimus, a P-glycoprotein and CYP3A4 substrate, increases everolimus exposure.\u00a0 Monitoring of everolimus levels and adverse effects is recommended when initiating cannabidiol therapy in patients taking this medication.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Coadministration of cannabidiol with everolimus, a P-glycoprotein and CYP3A4 substrate, increases everolimus exposure.\u00a0 Monitoring of everolimus levels and adverse effects is recommended when initiating cannabidiol therapy in patients taking this medication."}
{"id": "article-64046_35", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "The concurrent use of cannabidiol\u00a0with drugs like\u00a0valproate\u00a0increases the\u00a0risk of hepatotoxicity. [41] Liver function tests\u00a0should be performed regularly, and discontinuation or reduction of cannabidiol should be considered if there is significant hepatotoxicity.", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. The concurrent use of cannabidiol\u00a0with drugs like\u00a0valproate\u00a0increases the\u00a0risk of hepatotoxicity. [41] Liver function tests\u00a0should be performed regularly, and discontinuation or reduction of cannabidiol should be considered if there is significant hepatotoxicity."}
{"id": "article-64046_36", "title": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions", "content": "Clinicians\u00a0should be cautious about prescribing CBD with other sedative medications, such as benzodiazepines and opioids. Concomitant use of CBD with these sedative medications can result in severe respiratory depression. [42] [43]", "contents": "Cannabidiol (CBD) -- Adverse Effects -- Drug-Drug Interactions. Clinicians\u00a0should be cautious about prescribing CBD with other sedative medications, such as benzodiazepines and opioids. Concomitant use of CBD with these sedative medications can result in severe respiratory depression. [42] [43]"}
{"id": "article-64046_37", "title": "Cannabidiol (CBD) -- Contraindications", "content": "Absolute contraindications to CBD\u00a0include an allergy to cannabidiol or sesame oil. At the first signs of cutaneous irritation or anaphylactic reaction, the patient should stop using CBD. [44] [45]", "contents": "Cannabidiol (CBD) -- Contraindications. Absolute contraindications to CBD\u00a0include an allergy to cannabidiol or sesame oil. At the first signs of cutaneous irritation or anaphylactic reaction, the patient should stop using CBD. [44] [45]"}
{"id": "article-64046_38", "title": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions", "content": "Substance use disorder: In patients with a history of substance use disorder, providers should be cautious when prescribing CBD. While CBD does not contain the part of marijuana that gives users a \u201chigh,\u201d it may be addictive. Physicians should caution patients who have struggled with addiction about this and emphasize appropriate use. In these cases, clinicians should\u00a0determine\u00a0the risk vs. benefit ratio.", "contents": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions. Substance use disorder: In patients with a history of substance use disorder, providers should be cautious when prescribing CBD. While CBD does not contain the part of marijuana that gives users a \u201chigh,\u201d it may be addictive. Physicians should caution patients who have struggled with addiction about this and emphasize appropriate use. In these cases, clinicians should\u00a0determine\u00a0the risk vs. benefit ratio."}
{"id": "article-64046_39", "title": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions", "content": "Suicidal ideations: Cannabidiol should be used with caution for patients with a history of mood disorders, depression, or suicidal thoughts; patients with a history of these should be cautioned about using CBD, as is\u00a0correlated with increased suicidal thoughts and behavior. Physicians should\u00a0determine the risk vs. benefit ratio and\u00a0advise patients and their caregivers to watch for sudden changes in behavior. [46] [36]", "contents": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions. Suicidal ideations: Cannabidiol should be used with caution for patients with a history of mood disorders, depression, or suicidal thoughts; patients with a history of these should be cautioned about using CBD, as is\u00a0correlated with increased suicidal thoughts and behavior. Physicians should\u00a0determine the risk vs. benefit ratio and\u00a0advise patients and their caregivers to watch for sudden changes in behavior. [46] [36]"}
{"id": "article-64046_40", "title": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions", "content": "Hepatotoxicity: Cholestatic\u00a0and mixed patterns of\u00a0drug-induced liver injury (based on the\u00a0alanine aminotransferase (ALT) to the upper limit of normal (ULN) and alkaline phosphatase (ALP) to ULN\u00a0ratios) have been reported in patients treated with cannabidiol.", "contents": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions. Hepatotoxicity: Cholestatic\u00a0and mixed patterns of\u00a0drug-induced liver injury (based on the\u00a0alanine aminotransferase (ALT) to the upper limit of normal (ULN) and alkaline phosphatase (ALP) to ULN\u00a0ratios) have been reported in patients treated with cannabidiol."}
{"id": "article-64046_41", "title": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions", "content": "Rapid discontinuation: Although improved seizure control has been observed\u00a0on a dosage of 20 mg/kg/d, this is accompanied by a higher incidence of adverse reactions. CBD use should not be discontinued abruptly. Sudden discontinuation can cause an increase in seizure frequency and possibly status epilepticus. [27]", "contents": "Cannabidiol (CBD) -- Contraindications -- Warnings and Precautions. Rapid discontinuation: Although improved seizure control has been observed\u00a0on a dosage of 20 mg/kg/d, this is accompanied by a higher incidence of adverse reactions. CBD use should not be discontinued abruptly. Sudden discontinuation can cause an increase in seizure frequency and possibly status epilepticus. [27]"}
{"id": "article-64046_42", "title": "Cannabidiol (CBD) -- Monitoring", "content": "Due to the potential negative effects of CBD on the liver, transaminase and bilirubin levels must be measured before and after\u00a0treatment initiation. If\u00a0these levels increase before treatment, this may be a sign of underlying liver damage. By measuring transaminase levels during treatment, earlier identification of potential liver damage may be identified, and CBD dosing may be titrated down. These levels should be obtained 1 month before and 3 months after initiating treatment. After\u00a0any change in dose\u00a0or addition of a medication known to affect the liver, transaminase and bilirubin levels should be obtained\u00a0monthly\u00a0from patients who have liver damage or take drugs known to cause hepatotoxicity (eg, valproate, clobazam).", "contents": "Cannabidiol (CBD) -- Monitoring. Due to the potential negative effects of CBD on the liver, transaminase and bilirubin levels must be measured before and after\u00a0treatment initiation. If\u00a0these levels increase before treatment, this may be a sign of underlying liver damage. By measuring transaminase levels during treatment, earlier identification of potential liver damage may be identified, and CBD dosing may be titrated down. These levels should be obtained 1 month before and 3 months after initiating treatment. After\u00a0any change in dose\u00a0or addition of a medication known to affect the liver, transaminase and bilirubin levels should be obtained\u00a0monthly\u00a0from patients who have liver damage or take drugs known to cause hepatotoxicity (eg, valproate, clobazam)."}
{"id": "article-64046_43", "title": "Cannabidiol (CBD) -- Monitoring", "content": "Transaminase and total bilirubin levels should be obtained immediately at the first signs of liver dysfunction, such as right upper quadrant pain, nausea, vomiting, jaundice, and dark urine. If transaminase levels are greater than\u00a05 times the upper limit of normal or greater than\u00a03 times the upper limit, and bilirubin levels are greater than\u00a02 times the upper limit of normal, treatment should be discontinued. [47] [48]", "contents": "Cannabidiol (CBD) -- Monitoring. Transaminase and total bilirubin levels should be obtained immediately at the first signs of liver dysfunction, such as right upper quadrant pain, nausea, vomiting, jaundice, and dark urine. If transaminase levels are greater than\u00a05 times the upper limit of normal or greater than\u00a03 times the upper limit, and bilirubin levels are greater than\u00a02 times the upper limit of normal, treatment should be discontinued. [47] [48]"}
{"id": "article-64046_44", "title": "Cannabidiol (CBD) -- Monitoring", "content": "According to ASCO guidelines, hepatotoxicity is predominantly observed in adult and pediatric populations administered oral CBD at daily doses of 300 mg or\u00a0greater. Federal legislation has sanctioned cannabis with increased\u00a0CBD levels and minimal THC content. [13] The American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends delaying elective surgery for a minimum of 2 hours after cannabis smoking due to the increased perioperative risk of acute myocardial infarction. [49]", "contents": "Cannabidiol (CBD) -- Monitoring. According to ASCO guidelines, hepatotoxicity is predominantly observed in adult and pediatric populations administered oral CBD at daily doses of 300 mg or\u00a0greater. Federal legislation has sanctioned cannabis with increased\u00a0CBD levels and minimal THC content. [13] The American Society of Regional Anesthesia and Pain Medicine (ASRA) recommends delaying elective surgery for a minimum of 2 hours after cannabis smoking due to the increased perioperative risk of acute myocardial infarction. [49]"}
{"id": "article-64046_45", "title": "Cannabidiol (CBD) -- Toxicity", "content": "Reports of required ventilation support for children and older\u00a0adults\u00a0after ingesting\u00a0excessive\u00a0cannabis amounts have been documented. [50] CBD is associated with worsening respiratory depression in patients taking other respiratory-depressing drugs, such as opioids and benzodiazepines. In these scenarios, respiratory support is the mainstay of treatment; there is no antidote to CBD or cannabis toxicity. [11] [51] [47] [50]", "contents": "Cannabidiol (CBD) -- Toxicity. Reports of required ventilation support for children and older\u00a0adults\u00a0after ingesting\u00a0excessive\u00a0cannabis amounts have been documented. [50] CBD is associated with worsening respiratory depression in patients taking other respiratory-depressing drugs, such as opioids and benzodiazepines. In these scenarios, respiratory support is the mainstay of treatment; there is no antidote to CBD or cannabis toxicity. [11] [51] [47] [50]"}
{"id": "article-64046_46", "title": "Cannabidiol (CBD) -- Enhancing Healthcare Team Outcomes", "content": "FDA\u00a0approval of CBD for the treatment of Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous sclerosis complex has\u00a0significantly improved\u00a0the lives of patients and their families. Pediatric neurologists should be consulted for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Due to CBD's\u00a0adverse effects (particularly on the liver),\u00a0regular\u00a0liver function monitoring is recommended.\u00a0Pharmacists should perform medication reconciliation, report any significant drug interactions, and educate\u00a0caregivers on potential adverse effects. Nurses are vital in educating patients about proper dosing, monitoring, and providing support throughout treatment.\u00a0CBD's therapeutic potential may be far more widespread than initially believed;\u00a0researchers and clinicians\u00a0should continue to evaluate and identify\u00a0CBD's uses. Due to differing state laws\u00a0regarding\u00a0marijuana, social workers and other relevant healthcare professionals must help caregivers\u00a0and patients understand that CBD is legal and is not the part of cannabis that makes its users high. Proper\u00a0administration of CBD has demonstrated a reduction in seizure frequency in these syndromes, which are notoriously difficult to treat. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, neurologists, and nurses are necessary to\u00a0optimize outcomes for\u00a0patients on cannabidiol therapy.", "contents": "Cannabidiol (CBD) -- Enhancing Healthcare Team Outcomes. FDA\u00a0approval of CBD for the treatment of Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous sclerosis complex has\u00a0significantly improved\u00a0the lives of patients and their families. Pediatric neurologists should be consulted for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Due to CBD's\u00a0adverse effects (particularly on the liver),\u00a0regular\u00a0liver function monitoring is recommended.\u00a0Pharmacists should perform medication reconciliation, report any significant drug interactions, and educate\u00a0caregivers on potential adverse effects. Nurses are vital in educating patients about proper dosing, monitoring, and providing support throughout treatment.\u00a0CBD's therapeutic potential may be far more widespread than initially believed;\u00a0researchers and clinicians\u00a0should continue to evaluate and identify\u00a0CBD's uses. Due to differing state laws\u00a0regarding\u00a0marijuana, social workers and other relevant healthcare professionals must help caregivers\u00a0and patients understand that CBD is legal and is not the part of cannabis that makes its users high. Proper\u00a0administration of CBD has demonstrated a reduction in seizure frequency in these syndromes, which are notoriously difficult to treat. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, neurologists, and nurses are necessary to\u00a0optimize outcomes for\u00a0patients on cannabidiol therapy."}
{"id": "article-64046_47", "title": "Cannabidiol (CBD) -- Enhancing Healthcare Team Outcomes", "content": "CBD reduces seizures and increases seizure control. In particular, CBD, used as an adjunct therapy in Lennox-Gastaut syndrome or Dravet syndrome without seizure control by anti-epileptics, significantly reduces seizure frequency. [10] CBD is known to cause hepatotoxicity;\u00a0periodic liver\u00a0function testing (LFTs) is necessary. [47]", "contents": "Cannabidiol (CBD) -- Enhancing Healthcare Team Outcomes. CBD reduces seizures and increases seizure control. In particular, CBD, used as an adjunct therapy in Lennox-Gastaut syndrome or Dravet syndrome without seizure control by anti-epileptics, significantly reduces seizure frequency. [10] CBD is known to cause hepatotoxicity;\u00a0periodic liver\u00a0function testing (LFTs) is necessary. [47]"}
{"id": "article-64046_48", "title": "Cannabidiol (CBD) -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Cannabidiol (CBD) -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}